Hypocholesterolemic effects and safety of capsules containing heat-sterilized
Lactobacillus paracasei NLB163 isolated from Funazushi (NLB163 capsule) were investigated in a double blind, placebo-controlled, parallel design trial. The subjects included adult males and females with boundary and mild hypercholesterolemia (serum total cholesterol level=202-268mg/dL, serum LDL cholesterol level=121-180mg/dL), who were not taking hypocholesterolemic medicine. Subjects were randomly divided into the NLB163 and placebo groups and given NLB163 capsules (containing 100mg of heat-sterilized
L. paracasei NLB163 powder) and placebo capsules, respectively, at doses of 2 capsules 3 times a day for 6 weeks. NLB163 capsule intake significantly decreased the serum levels of total cholesterol by 9.4% (
p<0.01) and LDL cholesterol by 13.2% (
p<0.05), whereas placebo capsule intake showed no significant changes ; these levels decreased in most subjects of NLB163 group. Moreover, no hematological, blood biochemical, physical, or clinical change indicative of an adverse reaction was observed following NLB163 capsule intake. These results demonstrate the benefits and safety of
L. paracasei NLB163 in subjects with boundary and mild hypercholesterolemia.
View full abstract